Pharming Group Q2 2025 Financial Results and Business Update

SEC Filing 6-K (0001828316-25-000034)

Pharming Group N.V. reported a 26% increase in total revenues for Q2 2025, reaching $93.2 million, driven by strong growth in RUCONEST® and Joenja® sales. RUCONEST® revenue grew by 28% to $80.4 million, while Joenja® revenue increased by 15% to $12.8 million. The company achieved an operating profit of $10.8 million, compared to a loss of $3.1 million in Q2 2024. Pharming raised its full-year revenue guidance to $335-$350 million, up from the previous $325-$340 million. The company also highlighted progress in its clinical pipeline, including the submission of a new drug application for leniolisib in Japan and advancements in the FALCON trial for KL1333. Pharming's cash and marketable securities increased to $130.8 million at the end of Q2 2025.